Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective
Purpose: To analyze the outcomes of botulinum toxin A injection in acute acquired comitant esotropia (AACE). Methods: This is a retrospective study that included cases diagnosed as AACE between January 2022 and February 2023. Patients who were treated with Botox and completed a minimum 3 months foll...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-02-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/IJO.IJO_2198_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087286316007424 |
|---|---|
| author | Akshay Badakere Vibha Badrinath Hennaav Kaur Dhillon Abinaya Valliappan Viswanathan Natarajan Sumita Agarkar |
| author_facet | Akshay Badakere Vibha Badrinath Hennaav Kaur Dhillon Abinaya Valliappan Viswanathan Natarajan Sumita Agarkar |
| author_sort | Akshay Badakere |
| collection | DOAJ |
| description | Purpose:
To analyze the outcomes of botulinum toxin A injection in acute acquired comitant esotropia (AACE).
Methods:
This is a retrospective study that included cases diagnosed as AACE between January 2022 and February 2023. Patients who were treated with Botox and completed a minimum 3 months follow-up were included in the study. All the patients underwent a complete ophthalmic, orthoptic examination and neuroimaging. The effects of age, onset of esotropia, screen time, deviation pre injection, mode of injection (transconjunctival/ open sky) and whether injection was administered in one/both eyes on successful outcome were analysed.
Results:
Twenty-seven patients (20 male, seven female) were included in the study. The median age was 10 years. The median deviation for distance and near preinjection was 35 and 40 prism diopters, respectively. Complete resolution of symptoms was noted in 18 patients (66.6%). Four patients needed prisms, two required repeat injections, and one each needed surgery and divergence therapy. Six patients developed ptosis. None of the risk factors seemed to affect outcomes.
Conclusion:
Botulinum toxin injected into the medial rectus is a safe and viable option for AACE. Preinjection counseling about ptosis, recurrence needing prisms, reinjection, or surgery is important. |
| format | Article |
| id | doaj-art-f844255be7bc4cf79d68e5d7a91698bf |
| institution | Kabale University |
| issn | 0301-4738 1998-3689 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj-art-f844255be7bc4cf79d68e5d7a91698bf2025-02-06T05:39:35ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892025-02-0173222823010.4103/IJO.IJO_2198_23Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspectiveAkshay BadakereVibha BadrinathHennaav Kaur DhillonAbinaya ValliappanViswanathan NatarajanSumita AgarkarPurpose: To analyze the outcomes of botulinum toxin A injection in acute acquired comitant esotropia (AACE). Methods: This is a retrospective study that included cases diagnosed as AACE between January 2022 and February 2023. Patients who were treated with Botox and completed a minimum 3 months follow-up were included in the study. All the patients underwent a complete ophthalmic, orthoptic examination and neuroimaging. The effects of age, onset of esotropia, screen time, deviation pre injection, mode of injection (transconjunctival/ open sky) and whether injection was administered in one/both eyes on successful outcome were analysed. Results: Twenty-seven patients (20 male, seven female) were included in the study. The median age was 10 years. The median deviation for distance and near preinjection was 35 and 40 prism diopters, respectively. Complete resolution of symptoms was noted in 18 patients (66.6%). Four patients needed prisms, two required repeat injections, and one each needed surgery and divergence therapy. Six patients developed ptosis. None of the risk factors seemed to affect outcomes. Conclusion: Botulinum toxin injected into the medial rectus is a safe and viable option for AACE. Preinjection counseling about ptosis, recurrence needing prisms, reinjection, or surgery is important.https://journals.lww.com/10.4103/IJO.IJO_2198_23acquiredacutebotulinum toxinesotropiasurgery |
| spellingShingle | Akshay Badakere Vibha Badrinath Hennaav Kaur Dhillon Abinaya Valliappan Viswanathan Natarajan Sumita Agarkar Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective Indian Journal of Ophthalmology acquired acute botulinum toxin esotropia surgery |
| title | Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective |
| title_full | Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective |
| title_fullStr | Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective |
| title_full_unstemmed | Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective |
| title_short | Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective |
| title_sort | botulinum toxin a as a treatment modality for acute acquired comitant esotropia an indian perspective |
| topic | acquired acute botulinum toxin esotropia surgery |
| url | https://journals.lww.com/10.4103/IJO.IJO_2198_23 |
| work_keys_str_mv | AT akshaybadakere botulinumtoxinaasatreatmentmodalityforacuteacquiredcomitantesotropiaanindianperspective AT vibhabadrinath botulinumtoxinaasatreatmentmodalityforacuteacquiredcomitantesotropiaanindianperspective AT hennaavkaurdhillon botulinumtoxinaasatreatmentmodalityforacuteacquiredcomitantesotropiaanindianperspective AT abinayavalliappan botulinumtoxinaasatreatmentmodalityforacuteacquiredcomitantesotropiaanindianperspective AT viswanathannatarajan botulinumtoxinaasatreatmentmodalityforacuteacquiredcomitantesotropiaanindianperspective AT sumitaagarkar botulinumtoxinaasatreatmentmodalityforacuteacquiredcomitantesotropiaanindianperspective |